IPO Timeline Raw facts
Company Overview
| Stock Name | Genfleet-B |
|---|---|
| Stock Code | 02595 |
| Company Full Name | GenFleet Therapeutics (Shanghai) Inc. |
| Industry | New Energy |
| Principal Activities | biopharmaceutical company based in China, featuring a global vision, international collaborations and operations |
| Listing Date | 2025-09-19 |
| Listing Rules Era | New Rules (after Aug 2025) |
| Listing Rules Chapter | Chapter 18A |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 1206 Zhangjiang Road (Shanghai) Pilot Free Trade Zone PRC |
| Business Address (Hong Kong) | 香港灣仔皇后大道東183號合和中心46樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.genfleet.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | Computershare Hong Kong Investor |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 20.39 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 200 shares |
| Entry Threshold | HK$ 4,078 |
| Par Value | RMB 0.1 / shares |
| Offer Period | 2025-09-11 to 2025-09-16 |
| Global Offering Shares | 89,240,000 shares |
| HK Public Offer Shares (Initial) | 7,760,000 shares (10.0%) |
| Public Offer Lots (Initial) | 38,800lots (Pool A19,400lots,Pool B19,400lots) |
| International Placing Shares (Initial) | 69,840,000 shares (90.0%) |
| Offer Ratio | ~25.84% |
| Total Shares Post-IPO | 345,340,630 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | 中信证券(香港)有限公司 CE AAK249 |
| Cornerstone Share | 42.9% |
| Clawback Tiers | Mechanism B: no clawback |
| Reallocation Option | No |
| Total Global Offering Size | HK$ 1,819,603,600 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 200 | HK$ 4,078 |
| 2 lots | 400 | HK$ 8,156 |
| 3 lots | 600 | HK$ 12,234 |
| 4 lots | 800 | HK$ 16,312 |
| 5 lots | 1,000 | HK$ 20,390 |
| 6 lots | 1,200 | HK$ 24,468 |
| 7 lots | 1,400 | HK$ 28,546 |
| 8 lots | 1,600 | HK$ 32,624 |
| 9 lots | 1,800 | HK$ 36,702 |
| 10 lots | 2,000 | HK$ 40,780 |
| 15 lots | 3,000 | HK$ 61,170 |
| 20 lots | 4,000 | HK$ 81,560 |
| 25 lots | 5,000 | HK$ 101,950 |
| 30 lots | 6,000 | HK$ 122,340 |
| 35 lots | 7,000 | HK$ 142,730 |
| 40 lots | 8,000 | HK$ 163,120 |
| 45 lots | 9,000 | HK$ 183,510 |
| 50 lots | 10,000 | HK$ 203,900 |
| 100 lots | 20,000 | HK$ 407,800 |
| 150 lots | 30,000 | HK$ 611,700 |
| 200 lots | 40,000 | HK$ 815,600 |
| 250 lots | 50,000 | HK$ 1,019,500 |
| 300 lots | 60,000 | HK$ 1,223,400 |
| 350 lots | 70,000 | HK$ 1,427,300 |
| 400 lots | 80,000 | HK$ 1,631,200 |
| 450 lots | 90,000 | HK$ 1,835,100 |
| 500 lots | 100,000 | HK$ 2,039,000 |
| 750 lots | 150,000 | HK$ 3,058,500 |
| 1,000 lots | 200,000 | HK$ 4,078,000 |
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1,250 lots | 250,000 | HK$ 5,097,500 |
| 1,500 lots | 300,000 | HK$ 6,117,000 |
| 1,750 lots | 350,000 | HK$ 7,136,500 |
| 2,000 lots | 400,000 | HK$ 8,156,000 |
| 2,250 lots | 450,000 | HK$ 9,175,500 |
| 2,500 lots | 500,000 | HK$ 10,195,000 |
| 3,000 lots | 600,000 | HK$ 12,234,000 |
| 3,500 lots | 700,000 | HK$ 14,273,000 |
| 4,000 lots | 800,000 | HK$ 16,312,000 |
| 4,500 lots | 900,000 | HK$ 18,351,000 |
| 5,000 lots | 1,000,000 | HK$ 20,390,000 |
| 7,500 lots | 1,500,000 | HK$ 30,585,000 |
| 10,000 lots | 2,000,000 | HK$ 40,780,000 |
| 12,500 lots | 2,500,000 | HK$ 50,975,000 |
| 15,000 lots | 3,000,000 | HK$ 61,170,000 |
| 19,400 lots | 3,880,000 | HK$ 79,113,200 |
Stock Connect Inclusion Analysis
| HK Market Cap | HK$ 10.41B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 7,041,495,445 |
|---|---|
| H-Share Market Cap (at Offer Price) | HK$ 6,619,471,177 |
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not applicable (loss-making) |
| Profit/Loss Status | Net loss RMB 677.6 million |
| Period-End Cash Balance | RMB 362.12 million |
| Listing Expenses | ~HK$ 138,800,000 |
| Listing Expenses / Funds Raised | ~8.8% |
| Total Pre-IPO Investment | approximately RMB 1,421 million |
| First Day Close | HK$ 42.1 |
|---|---|
| First Day Open | HK$ 44.0 |
| First Day Change | 106.47% |
| First Day Volume | 34913500.0 |
| First Day Turnover | 1552900000.0 |
| Use of Proceeds | 1、約1,024.9百萬港元(或約71.0%)將用作核心產品GFH925及GFH375的進一步開發資金;
2、約274.3百萬港元(或約19.0%)將用作為其他候選產品的開發提供資金;
3、約144.4百萬港元(或約10%)將用作營運資金及其他一般企業用途。 |
Underwriting Syndicate
Service Providers
| Role | Institution |
|---|---|
| Legal Advisor to Company |
Davis Polk & Wardwell 嘉源律师事务所 君合律师事务所 Jun He Law Offices P.C. |
| Legal Advisor to Sponsors/Underwriters |
苏利文•克伦威尔律师事务所(香港)有限法律责任合伙 竞天公诚律师事务所 |
| Auditor and Reporting Accountant | 安永会计师事务所 |
| Industry Advisor | 弗若斯特沙利文(北京)咨询有限公司上海分公司 |
| Compliance Advisor | 国泰君安融资有限公司 CE AGS488 |
| Receiving Banks | 中信银行(国际)有限公司 |
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Lake Bleu Innovation Healthcare Master Fund Limited | 16,838,062 HKD | — | 0.93% | — | 6 months | 2026-03-19 |
| 2 | Lake Bleu Prime Healthcare Master Fund Limited | 29,859,116 HKD | — | 1.64% | — | 6 months | 2026-03-19 |
| 3 | LBC HK Opportunity Fund Limited | 31,261,948 HKD | — | 1.72% | — | 6 months | 2026-03-19 |
| 4 | OrbiMed Funds | 97,447,888 HKD | — | 5.35% | — | 6 months | 2026-03-19 |
| 5 | RTW Funds | 116,940,728 HKD | — | 6.43% | — | 6 months | 2026-03-19 |
| 6 | TruMed | 97,447,888 HKD | — | 5.36% | — | 6 months | 2026-03-19 |
| 7 | UBS Asset Management (Singapore) Ltd. | 77,959,126 HKD | — | 4.28% | — | 6 months | 2026-03-19 |
| 8 | Vivo Funds | 77,959,126 HKD | — | 4.28% | — | 6 months | 2026-03-19 |
| 9 | 富国基金管理有限公司 | 62,368,932 HKD | — | 3.43% | — | 6 months | 2026-03-19 |
| 10 | 富国资产管理(香港)有限公司 | 15,590,194 HKD | — | 0.86% | — | 6 months | 2026-03-19 |
| 11 | 汇添富基金管理股份有限公司 | 15,590,194 HKD | — | 0.86% | — | 6 months | 2026-03-19 |
| 12 | 汇添富资产管理(香港)有限公司 | 62,368,932 HKD | — | 3.43% | — | 6 months | 2026-03-19 |
| 13 | 中信证券国际资本管理有限公司 | 77,959,126 HKD | — | 4.28% | — | 6 months | 2026-03-19 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 呂強 | — |
| Company Secretary | 張巍 | — |
Major Shareholders
| Major Shareholders & Holdings | Dr. Lü holds approximately 19.57% equity interest (after the Global Offering) through Shanghai Kunjin and Jianfa Hong Kong; Dr. Lan holds approximately 15.56% equity interest through Jianfa Hong Kong; Ourea Biotech holds approximately 6.49% equity interest; Changxing holds approximately 4.37% equity interest; Hongyong Bingde holds approximately 3.81% unlisted shares; Sinopharm Zhongsheng holds approximately 1.37% equity interest and 1.37% unlisted shares; CSPC Group Enbipu holds approximately 1.28% unlisted shares; Pu'en Guoxin holds approximately 1.15% unlisted shares; Huajin Lingjian holds approximately 0.68% equity interest and 0.68% unlisted shares; Bank of Communications Sci-Tech Innovation holds approximately 0.55% unlisted shares. |
|---|
Market Sentiment
The IPO of 劲方医药-B recorded an extreme oversubscription ratio of 2,662.79x, indicating frenzy-level retail demand. A hit rate of just 12.76% reflects severe allocation scarcity, and the offer price was fixed at HK$20.39 with no range to anchor expectations. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Tier Analysis
Without detailed tier distribution data, specific inefficiencies like 甲尾 vs 乙头 cannot be assessed. Reallocation from the international tranche was triggered, suggesting strong retail demand overwhelmed the 8.7% initial public offer portion, but the impact on allocation tiers is unclear. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice. Data may contain errors or omissions; verify against official filings.)
Demographics
Official demographic data for subscribed investors is unavailable. For biotech listings with such extreme oversubscription, a high proportion of mainland retail participation is typical, but no breakdown is provided. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)




